Molecular Formula | C68H109N17O22S2 |
Molar Mass | 1580.84 |
Density | 1.327 |
Boling Point | 1968.7±65.0 °C(Predicted) |
pKa | 3.15±0.10(Predicted) |
Storage Condition | -20°C |
In vitro study | Disitertide (100 μg/mL) suppresses the protein expression levels of PI3K and p-Akt, and induce the protein expression of Bax in MC3T3-E1 cells. Disitertide (TGF-β1 inhibitor) abrogates the MACC1- AS1 expression in GC cells, suggesting that targeting TGFβ signaling pathway may be a potential strategy to inhibit MSC-induced stemness and chemoresistance. Disitertide (P144, 10 μg/mL to 200 μg/mL) affects proliferation, induces apoptosis as well as anoikis in A172 and U-87 MG GBM cell lines. Western Blot Analysis Cell Line: Mouse embryo osteoblast precursor MC3T3-E1 cells. Concentration: 100 μg/mL. Incubation Time: 4 h. Result: Significantly suppressed the protein expression levels of PI3K and p-Akt, and induce the protein expression of Bax in MC3T3-E1 cells compared with the miR-590 group. |
In vivo study | Disitertide (Topical application, 300 μg/mL) may promote scar maturation and clinical improvement of hypertrophic scar morphology features in an “in vivo” model in nude mice after two weeks of treatment. Animal Model: Human hypertrophic scars were implanted in 60 nude mice. Dosage: 300 μg/mL was added the Lipogel. Administration: Topical application daily administered. Result: Successful shedding was achieved in 83,3% of the xenografts. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 0.633 ml | 3.163 ml | 6.326 ml |
5 mM | 0.127 ml | 0.633 ml | 1.265 ml |
10 mM | 0.063 ml | 0.316 ml | 0.633 ml |
5 mM | 0.013 ml | 0.063 ml | 0.127 ml |